Ken Griffin Kiniksa Pharmaceuticals, Ltd. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$17.63 - $21.74 $49,364 - $60,871	-2,800 Reduced 23.53%	9,100 $179,000
Q4 2023 Feb 14, 2024	SELL	$14.37 - $19.07 $64,665 - $85,815	-4,500 Reduced 27.44%	11,900 $208,000
Q3 2023 Nov 14, 2023	BUY	$13.62 - $20.2 $20,430 - $30,300	1,500 Added 10.07%	16,400 $284,000
Q2 2023 Aug 14, 2023	SELL	$10.44 - $16.48 $1.36 Million - $2.15 Million	-130,700 Reduced 89.77%	14,900 $209,000
Q1 2023 May 15, 2023	SELL	$10.7 - $15.79 $173,340 - $255,798	-16,200 Reduced 10.01%	145,600 $1.57 Million
Q4 2022 Feb 14, 2023	BUY	$11.42 - $17.05 $983,262 - $1.47 Million	86,100 Added 113.74%	161,800 $2.42 Million
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $33,184 - $45,594	3,400 Added 4.7%	75,700 $972,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $698M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.